The GCFLU Quadrivalent from Green Cross Corp. - quiet protection with four strains for seasonal peaks

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-28, 03:35. Details in the imprint.

The GCFLU Quadrivalent sits cold and ready in a stainless-steel tray, the clear liquid glinting under the clinic's neon light as a nurse rolls up a patient's sleeve. One short sting, a quiet pressure, and a whole flu season's worry shrinks to a routine errand.

What GCFLU Quadrivalent does

GCFLU Quadrivalent from Green Cross Corp. is an inactivated seasonal influenza vaccine that targets four strains at once, two A subtypes and two B lineages in line with WHO recommendations. It is designed for use in adolescents and adults from 9 years of age in the Korean market.

The formulation contains split virion antigens prepared from circulating influenza strains selected for the corresponding season, aiming to reduce symptomatic flu and complications such as pneumonia in vaccinated patients. Administration is via intramuscular injection, typically in the deltoid muscle, with a single dose per season for most healthy adults.

How it is positioned in Korea

GCFLU Quadrivalent has become a staple in Korean vaccination campaigns, used in hospitals, clinics and workplace programs when autumn approaches. Product manager Kim Ji-hyun at GC Biopharma has described the quadrivalent line as a "core backbone" of the company’s preventive portfolio in domestic tenders.

The vaccine slots into Korea’s broad immunization landscape alongside other Green Cross offerings such as GCFLU trivalent and pediatric variants, but the quadrivalent profile is increasingly preferred as health authorities push for wider strain coverage. That shift aligns with recommendations from national advisory committees that favor quadrivalent formulations over older trivalent options.

The experience at the clinic

On a typical October morning in Seoul, patients shuffle in with scarves half looped, the smell of hand sanitizer sharp in the air as GCFLU Quadrivalent doses move from coolers to syringes one by one. The injection itself is quick, a firm tap on the skin, a measured breath out.

Nurses usually warn of mild soreness at the injection site or a low-grade fever as the immune system engages, but for most working adults the inconvenience is limited to a tender arm for a day and a brief sense of fatigue. That trade-off tends to be accepted as the cost of avoiding days of heavy coughing and body aches.

Composition and safety profile

Each dose of GCFLU Quadrivalent contains 15 micrograms of hemagglutinin antigen from each of the four recommended strains, combined with standard excipients and preservative in a multidose vial format. The vaccine is produced under GMP conditions at GC Biopharma facilities in Korea, with batch release testing before distribution.

Adverse reactions reported in post-marketing surveillance are mostly local pain, redness and transient systemic symptoms such as headache or muscle aches, similar to competing quadrivalent influenza vaccines. Serious events remain rare relative to the large number of doses administered every season.

Where it falls short

Like all seasonal flu vaccines, GCFLU Quadrivalent cannot guarantee full protection, particularly when circulating strains drift from the ones selected months before. Effectiveness may be lower in elderly or immunocompromised patients, who sometimes require additional strategies such as high-dose formulations or antiviral backup.

The product also remains largely limited to the Korean market and selected export territories, which means international travelers often switch to locally available brands when abroad. For some patients, the need for yearly injections is a minor annoyance compared with longer-interval vaccines in other disease areas.

Pricing and access

In Korea, GCFLU Quadrivalent is generally procured in bulk for national and municipal programs, with unit prices negotiated in large tenders rather than posted at retail counters. Private clinics may charge around 20,000 to 30,000 won per shot depending on service fees, keeping it relatively accessible to middle-income households.

For high-risk groups such as seniors and certain chronic patients, government programs often cover the cost, turning the injection into a free, scheduled preventive visit rather than an out-of-pocket decision. That policy context supports stable, recurring volumes for Green Cross year after year.

Role inside GC Biopharma and shares

GCFLU Quadrivalent sits alongside GC Biopharma’s broader vaccine and plasma portfolio, which includes hepatitis, varicella and haemophilia products. Under the leadership of CEO Huh Eun-chul, the company has pushed to modernize its vaccine line while still relying on seasoned brands that generate predictable cash flow.

Green Cross Corp. shares (ISIN KR7006280002) trade on the Korea Exchange in Korean won, giving domestic investors direct exposure to recurring flu-vaccine demand and to the firm’s wider biologics pipeline.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.